1. Baseline tumor biopsies
Figure S6
CD163
Log2 Signal CD163
HPX
Mono
M(-)
M(IL-4)
M(IL-10)
CD206
Log2 Signal MRC1 A
p=0.019
p=7.8×10−6
n.s.
Log2 RPKM MRC1
control
treated
Liver
Colon
Lung
p<10−6 p=
Log2 RPKM CD163 B C
CD68
Log2 Signal CD68
CD1c
Log2 Signal CD1c
TCGA Primary Lung
Adenocarcinoma
Log2 read count MRC1
Log2 read count
R=0.719
R=0.56
Log2 RPKM
Baseline tumor biopsies D E

2. Figure S6. In silico derived data for CD1C, CD68, CD163 and CD206 markers among different cells, species and within the current clinical approach. A) CD163 and CD206 expression (represented by robust multi-array average of background-adjusted, normalized, and log2-transformed signal values from perfect match probes) in in vitro macrophage subsets under HPX B) CD163 and CD206 expression (represented by log2-transformed RPKM values) in cynomolgus tissue from vehicle control and RG7155-treated groups. C) Mφ marker CD68 and dendritic cell marker CD1c expression (represented by robust multi-array average of background-adjusted, normalized, and log2-transformed signal values from perfect match probes) in various immune cell types isolated from PBMCs of healthy donors. Data were re-processed from raw data (.CEL files) downloaded from Gene Expression Omnibus (GSE28490, Ref#S1). Red line marks limit of blank values, below which signal is indistinguishable from noise. D) Expression (represented by log2-transformed read count values) of CD206 plotted against CD68 and CD1c in lung adenocarcinoma cohort from TCGA. Read counts were obtained as Level 3 TCGA data (RSEM). The red line represents RSEM value of 100, an arbitrary cut-off below which expression is typically low to none. E) CD68 and CD1c expression (represented by log2-transformed RPKM values) of baseline tumor biopsy samples from 31 patients enrolled in the clinical phase 1 trial for RG7155. Correlation R= All correlation values were calculated using Spearman method.